Ibex Investors’s Usana Health Sciences USNA Stock Holding History

Ibex Investors’s Portfolio USNA Stock Details USNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,739	Closed	-$210K	–	249
2018 Q3	$210K	Sell	1,739 -1,699	-49%	-$211K	0.12%	112
2018 Q2	$396K	Buy	+3,438	New	+$376K	0.22%	80
2018 Q1	–	Sell	-3,516	Closed	-$264K	–	273
2017 Q4	$264K	Buy	+3,516	New	+$235K	0.15%	54

Other funds holding USNA

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ibex Investors's USNA Position: Q4 2018 in Review

Ibex Investors sold out of Usana Health Sciences (USNA) in Q4 2018, closing a stake of 1,739 shares — an estimated $210K sold.

Ibex Investors first reported a position in USNA in Q4 2017 and held it in 3 quarters. The position peaked at $396K in Q2 2018. 190 funds tracked by Wall St. Rank hold USNA as of Q4 2018.

Ibex Investors reported no remaining Usana Health Sciences position as of Q4 2018 after selling out during the quarter.
Ibex Investors sold 1,739 Usana Health Sciences shares in Q4 2018, an estimated $210K.
Ibex Investors first reported a position in Usana Health Sciences in Q4 2017 and held it in 3 quarters.
Ibex Investors's Usana Health Sciences position peaked at $396K in Q2 2018.
190 funds tracked by Wall St. Rank held Usana Health Sciences as of Q4 2018.

Based on Ibex Investors's 13F filing for Q4 2018, filed 13 Feb 2019.